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Abstract The circadian timing system controls about 40% of
the transcriptome and is important in the regulation of a wide
variety of biological processes including metabolic and pro-
liferative functions. Disruption of the circadian clock could
have significant effect on human health and has an important
role in the development of cancer. Here, we compared the
expression levels of core clock genes in primary colorectal
cancer (CRC), colorectal liver metastases (CRLM), and liver
tissue within the same patient. Surgical specimens of 15 un-
treated patients with primary CRC and metachronous CRLM
were studied. Quantitative real-time polymerase chain reac-
tion (qRT-PCR) was used to measure the expression of 10
clock genes: CLOCK, BMAL1, PER1, PER2, PER3, CRY1,
CRY2, CSNK1E, TIM, TIPIN, and 2 clock-controlled genes:
Cyclin-D1, and WEE1. Expression levels of 7 core clock
genes were downregulated in CRLM: CLOCK (p = 0.006),
BMAL1 (p = 0.003), PER1 (p = 0.003), PER2 (p = 0.002),
PER3 (p < 0.001), CRY1 (p = 0.002), and CRY2 (p < 0.001).
In CRC, 5 genes were downregulated: BMAL1 (p = 0.02),
PER1 (p = 0.004), PER2 (p = 0.008), PER3 (p < 0.001), and
CRY2 (p < 0.001). CSNK1E was upregulated in CRC
(p = 0.02). Cyclin-D1 and WEE1 were both downregulated
in CRLM and CRC. Related to clinicopathological factors, a
significant correlation was found between low expression of
CRY1 and female gender, and low PER3 expression and the
number of CRLM. Our data demonstrate that the core clock is
disrupted in CRLM and CRC tissue from the same patient.
This disruption may be linked to altered cell-cycle dynamics
and carcinogenesis.
Keywords Circadian clock . Rhythms . Colorectal liver
metastases . Colorectal cancer
Introduction
The circadian timing system controls important biological
processes, including metabolic and proliferative functions
[1–3]. The rhythmic behavior of these processes takes approx-
imately 24 h and is called circadian rhythm (rhythms of ap-
proximately 1 day). The circadian clock consists of a master
oscillator which is located in the neurons of the suprachias-
matic nuclei (SCN) in the anterior hypothalamus of the brain
[4–6]. The master circadian oscillator coordinates peripheral
circadian clocks through both the autonomic nervous system
and neuroendocrine systems in most cells of the body [7].
Peripheral circadian oscillators all consist of the same set of
clock genes but regulate their expression in a tissue-specific
way [8].
The human molecular clock system involves a set of core
clock genes that act in transcription-translation feedback
loops. The primary feedback loop consists of CLOCK (circa-
dian locomotor output cycles kaput) and BMAL1 (brain-mus-
cle Arnt-like protein 1) which heterodimerize and subsequent-
ly activate transcription of the Cryptochrome (CRY1 and
CRY2) and Period (PER1, PER2, and, PER3) genes by bind-
ing to E-box elements in their promoters. The PER and CRY
proteins translocate to the cytoplasm where PER proteins are
phosphorylated by CKIɛ. Phosphorylated PER proteins are
unstable and are degraded by ubiquitination. CRY proteins
promote the formation of PER/CRY complexes and re-enter
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the nucleus, where they inhibit the transcription of their own
genes by blocking CLOCK/BMAL1. This molecular core os-
cillator is coupled to circadian output processes through a
series of clock-controlled genes (CCGs), which together reg-
ulate about 40 % of the transcriptome [9–11].
Perturbations in the function of circadian clock genes may
have significant effects on human health, and may cause sleep
disorders, depression, and gastrointestinal and cardiovascular
diseases. Furthermore, the circadian timing system plays an
important role in the development of cancer. Epidemiological
studies have demonstrated that circadian disruption in shift
workers increases the risk of various epithelial cancers
[12–15]. An important part of the cell cycle is regulated by
the circadian clock. CLOCK/BMAL1 directly regulates cell-
cycle genes that control cell proliferation, DNA damage, and
apoptosis. These CCGs include WEE-1 and Cyclin-D1.
Disruption of the circadian timing system may lead to a
deregulated cell cycle which favors carcinogenesis [16].
It has been demonstrated that inhibition of Per1 caused
reduced apoptosis in HCT116 colon cancer cells, while over-
expression of Per1 leads to DNA damage-induced apoptosis
[17]. Inactivation of Per2 caused deregulation of Bmal1 ex-
pression which contributed to a high incidence of tumor for-
mation. In addition, mice deficient in Per2 showed an increase
in tumor formation after -radiation [18]. Recently, we showed
that the core clock machinery is severely disrupted in murine
colorectal liver metastases (CRLM) and that the presence of
tumor in the liver induces a phase shift in the liver and kidney
tissue clocks [19].
In humans, CRLMworsen the prognosis of almost 60 % of
patients with colorectal cancer [20]. In animal models, the
core clock machinery is disrupted in several types of cancer.
The functioning of the circadian clock in patients with CRLM
has remained unclear. A better understanding of how tumors
affect the circadian clock may help elucidate the role of the
clock in cancer patients. We therefore investigated the expres-
sion levels of core clock genes in human CRLM tissue, adja-
cent liver tissue, and the primary colorectal tumor.
Furthermore, we related the expression levels to clinicopath-
ological factors in these patients.
Material and methods
Patients
Surgical resection specimens of the primary colorectal tu-
mor, liver metastases, and adjacent normal liver tissue were
obtained from 15 CRLM (male: 8, female: 7) patients who
did not receive neo-adjuvant chemotherapy treatment. The
patients underwent surgery at the Erasmus MC Cancer
Institute, Erasmus University Medical Center, Rotterdam,
The Netherlands between January 2005 and January 2012.
Clinical data including tumor characteristics of these pa-
tients are shown in Table 1. All operations started between
8:00 a.m. and 11:00 a.m. and the average time patients
were in the operation room was 3.30 h. All tissues were
collected between 09:00 a.m. and 13:30 p.m. and immedi-
ately frozen into liquid nitrogen and stored at −80 °C until
further analysis. Informed consent was obtained from all
patients and the study was approved by the Ethics
Committee at our institution.
Sampling procedure
All surgical resection specimens from primary colorectal tu-
mor, liver metastases, and adjacent normal liver tissue were
first macroscopically, then microscopically identified by an
experienced pathologist. Frozen resection specimens were re-
trieved from the archives of the pathology department and at
least 1 cm in diameter of viable tumor tissue was included
using a frozen tissue slicer (Leica CM1850 UV, Leica
Biosystems). There was no admixture of stromal tissue and
no necrosis was identified in the included samples. Tumor
characteristics are shown in Table 1.
Fresh frozen tissue, RNA extraction, and cDNA synthesis
RNAwas isolated from all tissues by phenol extraction using
Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions. The amount of extracted
RNA was measured by Nanodrop Spectrophotometry
(Nanodrop Technology, Wilmington, DE, USA). To avoid
genomic DNA contamination, RNA was purified by DNAse
treatment (RQ1 RNase-Free DNase; Promega, Madison, WI,
USA). RNAwas then reverse transcribed into complementary
DNA (cDNA) using random primers (Invitrogen) and
Superscript II RT (Invitrogen). cDNA samples were stored
at −20 °C until further analysis.
Quantitative real-time reverse transcriptase polymerase
chain reaction
Gene expression was analyzed by quantitative real-time PCR
(qRT-PCR) to assess differential expression of clock genes in
CRC tissue, CRLM, and adjacent liver tissue using an
Applied Biosystems 7700 PCR machine (Foster City, CA,
USA). RT-PCR was performed using SYBR Green-based
Quantitect Primer Assay (Qiagen, Venlo, The Netherlands)
for 10 clock transcripts: CLOCK (QT00054481), BMAL1
(QT00011844), PER1 (QT00069265), PER2 (QT00011207),
PER3 (QT00097713), CRY1 (QT00025067), CRY2
(QT00094920), TIM (QT00019789), TIPIN (QT00054334),
CSNK1E (QT02323916), and 2 clock-controlled genes:
Cyclin-D1 (QT00495285), WEE1 (QT00038199). PCR reac-
tions were carried out in a total volume of 25μL using the
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Quantifast SYBR Green PCR kit (Qiagen, Venlo,
The Netherlands). Each sample was tested in triplicate accord-
ing to the following PCR protocol: 10 min at 50 °C, 5 min at
95 °C, followed by 40 cycles at 95 °C for 10 s, and at 60 °C for
30 s. ΔCt values of the genes of interest were calculated as
described by the method of Pfaffl et al. using the
glutaraldehyde-3-phosphate dehydrogenase (GAPDH;
QT00079247) as a housekeeping gene [21]. GAPDH is a
commonly accepted marker for normalization of qPCR data
obtained from human tissues. Triplicate values of GAPDH
showed low standard deviations, and a one-way ANOVA
analysis between GAPDH values of all tissues showed no
significant differences (p > 0.05).ΔCt values were normalized
to the averageΔCt of the normal liver tissue. The fold change
was calculated using the Pfaffl equation, 2-ΔΔCt. Results are
expressed as median with the interquartile range (IQR). The
IQR is the difference between the upper and lower quartiles
(IQR =Q3−Q1).
Statistical analysis
Gene expression levels of CRLM and CRC were compared
with those of adjacent liver tissue and calculated using the
Pfaffl equation, 2-ΔΔCt. To assess the statistical significance
of the up- or downregulation of genes, the Wilcoxon signed-
rank rest was used. Correlation analyses between gene expres-
sion levels and all nine clinical pathological factors was per-
formed using the Spearman correlation. All analyses were
corrected for multiple testing by the Bonferroni method. All
statistical tests were two-sided and performed using SPSS 21
for Windows software (Statistical Package for Social
Sciences, Chicago, IL). p < 0.05 was considered to be signif-
icant, unless otherwise mentioned.
Results
Clock gene mRNA expression in CRLM compared
to adjacent liver
To compare clock gene expression in CRLM with adja-
cent normal liver tissue, we analyzed mRNA expression
levels of 10 clock genes (CLOCK, BMAL1, PER1, PER2,
PER3, CRY1, CRY2, CSNK1E, TIM, TIPIN). Liver metas-
tasis and liver tissue were used from 15 patients. Relative
messenger RNA (mRNA) expression levels of clock
genes in the liver and CRLM are presented in Fig. 1.
Tumor samples were normalized to the average ΔCt of
the liver tissue, and 7 genes were subsequently observed
to be downregulated in CRLM: CLOCK (median = 0.46,
Q1–Q3 = 0.22–0.75, p = 0.006), BMAL1 (median = 0.21,
Q1–Q3 = 0.14–0.36, p = 0.003), PER1 (median = 0.14,
Q1–Q3 = 0.05–0.52, p = 0.003), PER2 (median = 0.63,
Q1–Q3 = 0.25–0.86, p = 0.002), PER3 (median = 0.14,
Q1–Q3 = 0.04–0.37, p < 0.001), CRY1 (median = 0.50,
Q1–Q3 = 0.32–0.98, p = 0.002), and CRY2 (median = 0.31,
Q1–Q3 = 0.09–0.61, p < 0.001). The expression levels of
TIM and TIPIN showed no significant difference (median =
0.81, Q1–Q3 = 0.73–1.04, p = 0.54, and median = 1.05,
Q1–Q3 = 0.62–1.48, p = 0.74, respectively).
Table 1 Characteristics of clinicopathological factors from 15 patients
evaluated for circadian rhythm and outcome
N (%) Male/female
Age (years), mean (±SD) 67.5 ± 9.8 M 66.9 ± 10.2
F 68.3 ± 10.0
Sex
Male (M)/female (F) 8/7
Number of metastases
1 7 (46.7) M4/F3
2 3 (20.0) M2/F1
3 2 (13.3) M1/F1
4 1 (6.7) M0/F1
5 1 (6.7) M0/F1
6 1 (6.7) M1/F0
Diameter of largest metastasis (cm)
1.20–2.20 5 (33.3) M2/F3
2.40–4.40 7 (46.7) M4/F3
5.00–9.00 3 (20.0) M2/F1
CRLM in number of segments
1 4 (26.7) M3/F1
2 6 (40.0) M3/F3
3 1 (6.7) M0/F1
4 4 (26.7) M2/F2
Primary tumor location
Ascending colon 2 (13.3) M1/F1
Transverse colon – –
Descending colon 5 (33.3) M4/F1
Ascending+descending colon 1 (6.7) M0/F1
Rectum 7 (46.7) M3/F4
Histological type CRC
Moderately differentiated adenocarcinoma 13 (86.7) M7/F6
Poorly differentiated adenocarcinoma 2 (13.3) M1/F1
Depth of tumor invasion CRC
T1 – –
T2 4 (26.7) M2/F2
T3 9 (60.0) M5/F4
T4 1 (6.7) M1/F0
Missing 1 (6.7) M0/F1
Lymph node metastasis CRC
N0 8 (53.3) M5/F3
N1–N2 7 (46.7) M3/F4
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Clock gene mRNA expression in the primary colon tumor
compared to liver tissue
To determine whether clock gene expression was also im-
paired in the primary tumor, we measured mRNA expression
levels of colorectal tumors of the same patients. Five of 10
genes were downregulated, namely BMAL1 (median = 0.37,
Q1–Q3 = 0.16–0.53, p = 0.02), PER1 (median = 0.13, Q1–
Q3 = 0.06–0.6, p = 0.004), PER2 (median = 0.33, Q1–
Q3 = 0.17–0.80, p = 0.008), PER3 (median = 0.09, Q1–
Q3 = 0.04–0.22, p < 0.001), CRY2 (median = 0.11, Q1–
Q3 = 0.07–0.20, p < 0.001). Again, CSNK1Ewas upregulated
(median = 1.35, Q1–Q3 = 1.11–2.22, p = 0.02). The expression
of four genes did not show significant differences: CLOCK
(median = 0.73, Q1–Q3 = 0.29–1.16, p = 0.43), CRY1 (medi-
an = 0.51, Q1–Q3= 0.47–1.30, p = 0.23), TIM (median = 1.04,
Q1–Q3 = 0.78–1.23, p = 0.52), TIPIN (median = 1.11, Q1–
Q3 = 0.53–1.43, p = 0.70) (Fig. 1).
Clock-controlled gene mRNA expression in CRLM
and CRC compared to liver tissue
To determine whether the expression of clock-controlled
genes was impaired in CRLM and the primary tumor, we
analyzed mRNA expression of 2 circadian output genes
(Cyclin-D1, and WEE-1). Cyclin-D1 was downregulated in
CRLM (median = 0.76, Q1–Q3 = 0.48–1.01, p = 0.02), and in
CRC (median = 0.59, Q1–Q3 = 0.39–0.95, p = 0.008). WEE-1
was also downregulated in CRLM (median = 0.79, Q1–
Q3 = 0.47–1.12, p = 0.04), and in CRC (median = 0.66, Q1–
Q3 = 0.33–1.24, p = 0.03) (Fig. 2).
Relation between clock gene mRNA expression levels
and clinicopathological factors
A statistically significant correlation was found between
CRLM mRNA levels of PER3 and the number of metastases.
Lower PER3 mRNA levels were found with an increasing
number of metastases (r = 0.645, p = 0.009) (Fig. 3a).
Another significant correlation was found between CRLM
CRY1 mRNA levels and patient gender. Lower CRY1
mRNA levels were found in female patients compared to male
patients (r = 0.700, p = 0.005) (Fig. 3b). There were no other
significant correlations found between mRNA expression
levels and clinicopathological factors.
Discussion
In the current study, we examined the expression levels of
clock and clock-controlled genes in colorectal liver metastases
(CRLM), the primary colorectal tumor, and liver tissue in
surgical resection specimens of CRC patients. We also studied
possible relations between gene expression levels and clinical
and pathological factors of these patients. We used quantita-
tive real-time polymerase chain reaction (qRT-PCR) to iden-
tify the expression levels of CLOCK, BMAL1, PER1, PER2,
PER3, CRY1, CRY2, CSKN1E, TIM, TIPIN, Cyclin-D1, and
WEE1. We observed a downregulation of core clock, as well
as of clock-controlled gene mRNA expression levels in both
liver metastases and colorectal cancer. The genes encoding
CLOCK and BMAL1, the two core clock proteins that
heterodimerize and drive transcription of clock (controlled)
genes, were both significantly downregulated in CRLM.
BMAL1 expression was also lowered in colorectal tumors. In
line with the lower expression levels of CLOCK and BMAL1,
genes activated by the CLOCK/BMAL1 complex, such as
PER1, PER2, PER3, CRY1, and CRY2 all show a significant
reduction in expression compared to normal liver tissue. The
only gene that was significantly upregulated in the primary
tumor was CSKN1E. We observed no differences in the ex-
pression levels of TIM and TIPIN.
To our knowledge, this is the first study describing down-
regulation of clock genes in human CRLM. Our findings are
in line with previous studies describing circadian disruption in
other malignancies. In more than 95 % of breast cancer tissue
from 55 women, expression levels of PER1, PER2, and PER3
were severely disrupted in comparison with adjacent non-
cancerous tissue [22]. Pancreatic cancer has a low incidence
rate, but is very aggressive with high mortality rates.
Especially PER1 and downstream effectors of the circadian
clock are lower expressed in pancreatic cancer which further
suggests they may act as tumor suppressor genes in healthy
tissue [23]. Our data are supported by a study in human pri-
mary colorectal cancer. A downregulation in expression of
BMAL1, PER1, PER2, PER3, and CRY2 was found.
Furthermore, differential expression of clock genes was asso-
ciated with differences in survival [24]. In a study of 202
untreated CRC patients, PER1 and PER3 expression levels
were significantly lower compared to normal tissue. In con-
trast, the expression of CLOCK and CKIɛ was significantly
higher in cancer tissue. PER2 was shown to be differentially
expressed related to survival, with a better survival corre-
sponding with a high PER2 expression [25].
In this study, the only gene that was significantly upregu-
lated in CRC and showed a trend towards increased
Fig. 1 mRNA expression levels of clock and clock-controlled genes in
the liver, colorectal liver metastases (CRLM), and colon tumor. The
relative mRNA expression of each gene of interest was normalized to
glutaraldehyde-3-phosphate dehydrogenase (GAPDH). ΔCt values
were normalized to the average ΔCt of the normal liver tissue. For each
gene, boxes show the median with the interquartile range (IQR =Q3
−Q1). Asterisks indicate significance of the difference in expression of
each gene in the liver as compared to CRLM and CRC as assessed by the
Wilcoxon signed-rank test (*p < 0.05, **p < 0.01, ***p < 0.001)
Tumor Biol. (2016) 37:13973–13981 13977
expression in CRLM was CSNK1E. The CSNK1E gene en-
codes the CKIɛ protein, whose main function is to regulate
circadian rhythm by phosphorylation and degradation of
Period genes [26]. We showed that PER1, PER2, and PER3
gene expression levels were all lower in cancer tissue than in
liver tissue, while CSNK1E gene expression was higher in can-
cer tissue. The decreased expression levels of both transcription
activator, (BMAL1), and transcription inhibitor genes (CRYs
and PERs) suggest that the clock in the primary tumor and
CRLM may be dampened and/or less robust. Upregulation of
CSNK1E may lead to enhanced phosphorylation of the PER2
protein which is known to destabilize the PER protein and
target it for ubiquitination and subsequent proteosomal degra-
dation. Furthermore, CKIɛ plays an essential role in the early
development of CRC. CKIɛ is involved in cell proliferation by
stabilizing β-catenin and mimicking the effect of WNT-signal-
ing. Subsequently, this will lead to increased levels ofβ-catenin
in the nucleus to control transcription and maintain tumorige-
nesis [27, 28]. Knocking down CSNK1E in a human sarcoma
cell line led to growth inhibition of cells, and CSNK1E was
found to be upregulated in ten different human cancer tissues
compared to normal tissue [29].
In contrast to others, we found no significant difference in
TIMELESS (TIM) and timeless-interacting protein (TIPIN)
mRNA expression levels. These genes interact with compo-
nents of the DNA replication system to regulate DNA repli-
cation processes under normal and stress conditions and are
essential in regulating different phases of the cell cycle [30].
Downregulation of TIM increased doxorubicin toxicity in
HCT116 cancer cells, and it is suggested that TIM inhibition
could be used to enhance cytotoxic effectiveness of chemo-
therapeutic drugs [31]. Downregulation of TIM and TIPIN
was found in kidney cancer patients compared to normal kid-
ney tissue [32].
To determine whether the disruption of the clock affects its
output in CRLM and CRC, we measured the expression of
two CCGs. The mRNA expression of WEE-1 was downreg-
ulated in CRLM as well as in CRC.WEE-1 is a nuclear kinase
which is involved in the regulation of cell-cycle progression, a
key regulator of mitoses. The circadian timing system plays an
important role in transcription of WEE-1. In Clock-mutant
mice, a low expression of WEE-1 was found [2]. The
mRNA expression of Cyclin-D1 was also downregulated in
CRLM and in CRC. Cyclin-D1 plays an important role in the
cell cycle as well, because it regulates the progression of cells
in G1/S transition [33]. The relevance of these perturbations
for both tumor biology and as biomarkers for prognosis war-
rants further study.
We related the expression levels of clock genes to clin-
ical and pathological factors. Low expression of PER3 was
correlated with a higher number of metastases. In another
study, low PER1 expression was correlated with the devel-
opment of CRLM in CRC patients [25]. We also found a
significant correlation between gender and the expression
of CRY1 in CRLM. The lowest levels of CRY1 mRNA
expression were found in female patients. This correlation
was also found in a study where differential expression
levels of core clock genes were determined in tumor spec-
imens of CRC patients [24]. The fact that female patients
show lower CRY1 expression levels could be related to a
difference in metabolic pathways and xenobiotic detoxifi-
cation between genders. In the Chronotherapy Group Trial,
including a schedule of chronomodulated delivery of che-
motherapy, female patients were shown to have shorter
survival and greater toxicity when treated with 5-
fluorouracil and leucovorin [34].
The mRNA expression levels of CRLM of all core clock
genes in this study show differential expression compared to
liver tissue. These results support the hypothesis of the appar-
ent coupling between the circadian rest-activity cycle and the
time-dependent toxicity of drugs, which may be exploited in
the field of chronotherapy. The basis of chronotherapy relies
Fig. 2 mRNA expression levels of the clock-controlled genes Cyclin-D1
and WEE1 in the liver, colorectal liver metastases (CRLM), and colon
tumor. The relative mRNA expression of each gene of interest was
normalized to glutaraldehyde-3-phosphate dehydrogenase (GAPDH).
ΔCt values were normalized to the average ΔCt of the normal liver
tissue. For each gene, boxes show the median with the interquartile
range (IQR =Q3−Q1). Asterisks indicate significance of the difference
in expression of each gene in the liver as compared to CRLM and CRC
as assessed by the Wilcoxon signed-rank test (*p < 0.05, **p < 0.01)
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on the principle of administering chemotherapy at times when
toxicity is expected to be lowest [35, 36]. A phase III study in
CRC patients has shown better tolerability and anti-tumor
activity compared with conventional therapy when chemo-
therapy was administered according to the least toxic dosing
times [34]. In a phase II study, patients with unresectable
CRLM were treated with chronotherapy and highly toxic he-
patic arterial infusion which resulted in a doubling of second-
ary surgical resection rates [37].
Albeit our study shows evidence of a disrupted timing sys-
tem in CRLM and CRC in patients, we studied a relatively
small cohort of patients. By expanding the number of patients,
more correlations might be found between mRNA expression
levels and clinicopathological factors. The mRNA expression
levels of CRC are normalized to the levels of the adjacent
liver, but not colon tissue. Based on experiments with rats, it
is expected that the circadian timing system in the colon is in
phase with that in the liver [38]. Furthermore, we were only
Fig. 3 Correlation between clock
gene mRNA expression levels,
CRLM, and gender. a The
correlation betweenPER3mRNA
expression levels in CRLM and
the number of metastases,
evaluated by Spearman test
(r = 0.645, p = 0.009). b The
correlation betweenCRY1mRNA
expression levels in CRLM and
patient gender evaluated by the
Spearman test (r = 0.700,
p = 0.005)
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able to study gene expression at the timepoint at which the
resection specimen was obtained. Since patients are operated
on at different times of the day, and surgical resections are not
procedures with a fixed time frame, this is a limitation inherent
to a clinical study. To further elucidate this issue, we are cur-
rently investigating the impact of clock gene expression levels
in cancer cells in vitro by knocking down and overexpressing
clock genes in various tumor cell lines, followed by systematic
phenotyping of cancer properties of the cell (i.e., proliferation
rate, cell migration and invasion properties, and drug
sensitivity).
In summary, the present study shows that there are differ-
ences in clock gene expression in the CRLM and CRC tissue
compared to the liver in patients without neo-adjuvant chemo-
therapy treatment. The differential expressionmight be related
to carcinogenesis, tumor burden, and survival, and supports
the application of chronomodulated chemotherapy.
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